Togaviridae Infections is an indication for drug development with over 90 pipeline drugs currently active. According to GlobalData, preregistered drugs for Togaviridae Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Togaviridae Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Togaviridae Infections overview
The Togaviridae is a family of enveloped, single-stranded, plus-strand RNA viruses. The Togaviridae include the major causes of infectious arthropod-borne equine encephalitides and are divided into two main groups: the Alphaviridae—including Eastern equine encephalitis (EEE), Western equine encephalitis (WEE), and Venezuelan equine encephalitis (VEE)—and the Flaviviridae, including West Nile virus (WNV). Human infections generally occur when people intrude on enzootic alphavirus transmission habitats and are fed upon by infected mosquitoes, or when alphaviruses emerge to cause epizootics and epidemics via host range changes.
For a complete picture of PTSR and LoA scores for drugs in Togaviridae Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
